Trials Annotator

Trial NCT03198559

View at ClinicalTrials.gov

Org. Study IDs: MSD IIS-55750

Last trial update was posted on 2024-02-09

MeSH Interventions

Disulfiram Vorinostat

MeSH Conditions

HIV Infections

Other Conditions

Stopping Reasons

A re-evaluation of research risks to participants were greater than originally anticipated

Limitations And Caveats

Early termination of the study lead to a small numbers of participants analyzed. Therefore there was insufficient power to measure the effect of the intervention. Other key limitations to this study include: only 2 participants received study drug; participants did not complete the full course of treatment as outlined in the study design; 1 participant missed Day 10 study medication, stopped study treatment on Day 17; 1 participant ceased study medication on Day 11;

Result Publications

McMahon JH, Evans VA, Lau JSY, Symons J, Zerbato JM, Chang J, Solomon A, Tennakoon S, Dantanarayana A, Hagenauer M, Lee S, Palmer S, Fisher K, Bumpus N, Heck CJS, Burger D, Wu G, Zuck P, Howell BJ, Zetterberg HH, Blennow K, Gisslen M, Rasmussen TA, Lewin SR. Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. AIDS. 2022 Jan 1;36(1):75-82. doi: 10.1097/QAD.0000000000003091. [PMID: 34586085] [DOI: 10.1097/QAD.0000000000003091]

Annotations

Category Annotations

No annotators decided on categories yet

Intervention Annotations

#	Outdated	Intervention				Condition
#	Outdated	Name		Route	DrugBank ID	Condition